Insider Financial

Sign Up Now For Our FREE Small Cap Newsletter!

No spam. No Hidden Fees. Unsubscribe Anytime.

NBG AVEO Jazz Buyout
Biotech

Is AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) About To Be Bought Out?

Here is an interesting one. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) is picking up some early week strength on the back of rumors that the company is in discussions with another company regarding takeover of the former by the latter. The interested party is reportedly Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ), the Dublin, Ireland based healthcare company that is currently valued at just shy of $10 billion.

The rumor has hit press on the back of this release and it’s something that, generally, we wouldn’t pay much attention to without further substantiation. In this instance, however, there is an interesting element of the situation suggests it might be worth keeping one eye on moving forward.

AVEO Daily Chart

AVEO Daily Chart

Our regular readers will know that AVEO is a company that we have covered on a few occasions over the last six months or so. We first highlighted it as part of our Biotech Catalyst series back in June, with the outcome of a regulatory application serving up a potential near-term reevaluation. The catalyst played out in our favor and the stock ran on the news. Specifically, we were looking at a drug called tivozanib and a program designed to underpin an approval for said drug in the treatment of patients with advanced renal cell carcinoma.

Fast forward to today and the drug is now approved in Europe following a successful advisory panel meeting and sentiment surrounding an expanded global approval effort is pretty positive.

So what is the deal with the latest rumors?

Well, as mentioned, the press release highlights Jazz as a potential suitor and suggests that the discussions are ongoing and could result in Jazz paying a substantial premium to current price if and when the deal goes through. Rumors right now put the acquisition price in the $15-19 range per share. To offer up some perspective, AVEO currently trades for just $3.66 a share. That’s a more than 300% premium using the conservative, low end of the just mentioned price range.

As noted above, these sorts of rumors are pretty common at this end of the biotechnology space and just because a blog has put out a press release pertaining to have some insider information doesn’t mean that the deal is a sure thing – not even close. So why are we paying it any attention?

Well, if it was any other company, we wouldn’t be. That it’s Jazz, however, makes this interesting?

Why?

Remember above when we said that tivozanib is approved in Europe? It is, but AVEO isn’t responsible for the commercialization campaign on the continent. Instead, the company has licensed the drug out to a company called EUSA Pharma, Inc, a Hertfordshire, UK based pharmaceutical company that operates a sort of distribution/supply type network in Europe and the US.

Again, why is this important?

EUSA Pharma, Inc is a privately held company and its parent organization is none other than Jazz Pharmaceuticals. So, to put all this another way, AVEO is already in bed with Jazz as the latter (or, more accurately, the latter’s subsidiary) is responsible for pushing the company’s lead portfolio asset in Europe. We don’t know the exact terms on which the AVEO, EUSA license are based, but the suggestion that Jazz would want to pick up rights to the drug in the US and elsewhere isn’t far fetched at all. Further, that the company might want to absorb AVEO as opposed to inking a bunch of additional licensing deals (which are going to get more and more costly as the drug picks up a regulatory green light in more and more regions) isn’t much of a stretch to imagine.

It’s a speculative claim, sure. These are rumors that are yet to be substantiated in any sense of the word. With that said, however, given the large potential for upside on a takeover in the above-discussed range, this one could well be worth a punt.

Check out our previous coverage of this one here.

We will be updating our subscribers as soon as we know more. For the latest updates on AVEO, sign up below!

Image courtesy of mathew lippincott via Flickr

Disclosure: We have no position in AVEO and have not been compensated for this article.

GET NOTIFIED
Sign up for our next MicroCap Runner ahead of the crowd!
We hate spam. No Hidden Fees. Unsubscribe Anytime.
Here's Why The AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Buyout Rumors Are Interesting
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

Enter Symbol For Report



For over five years, we have provided a free service to a countless number of traders featuring only the best in the microcap arena. Insider Financial focuses solely on short-term high probability trade opportunities.

Our alerts consist of Nasdaq, NYSE and high quality OTC companies that are capable of delivering outsized gains to you today, not a year from now. If you have an interest in the lucrative microcap sector, sign up to Insider Financial today!

GET NOTIFIED
Sign up for our next MicroCap Runner ahead of the crowd!
We hate spam. No Hidden Fees. Unsubscribe Anytime.

Copyright © 2017 Insider Financial powered by Hundred.

To Top

Sign up now for our FREE Small Cap Newsletter

Sign up now for our FREE Small Cap Newsletter